Micrograph showing vacuolar interface dermatitis, as may be seen in SLE. Credit: Nephron.

Provention Bio has dosed the first patients in its Phase Ib/IIa PREVAIL clinical trial of humanised diabody PRV-3279.

PRV-3279 targets the B-cell surface proteins, CD32B and CD79B.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The PREVAIL study comprises a Phase Ib trial in healthy volunteers, followed by a Phase IIa trial in patients with systemic lupus erythematosus (SLE).

During the randomised, double-blind, placebo-controlled, multiple-ascending dose Phase Ia study, the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of PRV-3279 will be evaluated in 16 healthy volunteers.

After completion, the Phase IIa portion of the study will be initiated in Lupus patients.

Provention Bio co-founder and chief scientific officer Francisco Leon said: “PRV-3279 offers an elegant mechanism of action designed to intercept and ameliorate the overactive B cell-driven pathology of lupus and other autoimmune diseases.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“We believe that PRV-3279 is uniquely differentiated to allow for rapid inhibition of activated B cells, while sparing non-activated B cells from depletion or inactivation, thereby offering the potential for a more effective yet safer alternative to current B-cell targeted therapies.”

Data from the first part of the study is expected in the first half of next year.

Results from a prior single-ascending dose Phase I study showed that PRV-3279 was well-tolerated.

A single dose of the humanised diabody also demonstrated an inhibitory effect on the immunogenicity of hepatitis A vaccine provided to volunteers at the time of the trial.

Provention is initially developing PRV-3279 for the interception of SLE, a chronic autoimmune disorder characterised by an abnormal overactivation of B cells and subsequent pathologic production of auto-antibodies.

In April, Provention Bio concluded patient enrolment in the Phase IIa PRINCE clinical trial of PRV-6527 for the treatment of patients with moderate-to-severe Crohn’s disease.